Haemonetics Competitors

Align Technology (NASDAQ:ALGN) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Profitability

This table compares Align Technology and Haemonetics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Align Technology and Haemonetics, as reported by MarketBeat.com.

Align Technology presently has a consensus price target of $475.4615, indicating a potential downside of 16.03%. Haemonetics has a consensus price target of $144.80, indicating a potential upside of 13.19%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts plainly believe Haemonetics is more favorable than Align Technology.

Volatility & Risk

Align Technology has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Insider and Institutional Ownership

85.8% of Align Technology shares are held by institutional investors. Comparatively, 96.2% of Haemonetics shares are held by institutional investors. 1.2% of Align Technology shares are held by company insiders. Comparatively, 1.6% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Align Technology and Haemonetics' revenue, earnings per share (EPS) and valuation.

Align Technology has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Align Technology beats Haemonetics on 9 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

Profitability

This table compares West Pharmaceutical Services and Haemonetics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares West Pharmaceutical Services and Haemonetics' top-line revenue, earnings per share (EPS) and valuation.

West Pharmaceutical Services has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for West Pharmaceutical Services and Haemonetics, as provided by MarketBeat.

West Pharmaceutical Services presently has a consensus price target of $310.00, indicating a potential upside of 9.54%. Haemonetics has a consensus price target of $144.80, indicating a potential upside of 13.19%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts clearly believe Haemonetics is more favorable than West Pharmaceutical Services.

Risk & Volatility

West Pharmaceutical Services has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Insider and Institutional Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 96.2% of Haemonetics shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 1.6% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

The Cooper Companies (NYSE:COO) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

95.8% of The Cooper Companies shares are held by institutional investors. Comparatively, 96.2% of Haemonetics shares are held by institutional investors. 1.4% of The Cooper Companies shares are held by company insiders. Comparatively, 1.6% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares The Cooper Companies and Haemonetics' revenue, earnings per share and valuation.

The Cooper Companies has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for The Cooper Companies and Haemonetics, as provided by MarketBeat.

The Cooper Companies currently has a consensus target price of $360.0769, suggesting a potential downside of 8.84%. Haemonetics has a consensus target price of $144.80, suggesting a potential upside of 13.19%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts clearly believe Haemonetics is more favorable than The Cooper Companies.

Profitability

This table compares The Cooper Companies and Haemonetics' net margins, return on equity and return on assets.

Risk & Volatility

The Cooper Companies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

DENTSPLY SIRONA (NASDAQ:XRAY) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for DENTSPLY SIRONA and Haemonetics, as provided by MarketBeat.

DENTSPLY SIRONA currently has a consensus target price of $51.7857, suggesting a potential downside of 13.73%. Haemonetics has a consensus target price of $144.80, suggesting a potential upside of 13.19%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts clearly believe Haemonetics is more favorable than DENTSPLY SIRONA.

Profitability

This table compares DENTSPLY SIRONA and Haemonetics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

96.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 96.2% of Haemonetics shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 1.6% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

DENTSPLY SIRONA has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Earnings & Valuation

This table compares DENTSPLY SIRONA and Haemonetics' revenue, earnings per share and valuation.

DENTSPLY SIRONA has higher revenue and earnings than Haemonetics. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats DENTSPLY SIRONA on 10 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Quidel (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Haemonetics and Quidel, as reported by MarketBeat.

Haemonetics currently has a consensus price target of $144.80, suggesting a potential upside of 13.19%. Quidel has a consensus price target of $245.60, suggesting a potential upside of 45.55%. Given Quidel's higher probable upside, analysts plainly believe Quidel is more favorable than Haemonetics.

Profitability

This table compares Haemonetics and Quidel's net margins, return on equity and return on assets.

Institutional & Insider Ownership

96.2% of Haemonetics shares are owned by institutional investors. Comparatively, 84.0% of Quidel shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by insiders. Comparatively, 14.1% of Quidel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Valuation and Earnings

This table compares Haemonetics and Quidel's top-line revenue, earnings per share (EPS) and valuation.

Haemonetics has higher revenue and earnings than Quidel. Haemonetics is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats Quidel on 8 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares Haemonetics and STAAR Surgical's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Haemonetics and STAAR Surgical, as reported by MarketBeat.

Haemonetics currently has a consensus price target of $144.80, suggesting a potential upside of 13.19%. STAAR Surgical has a consensus price target of $68.50, suggesting a potential downside of 34.82%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than STAAR Surgical.

Volatility and Risk

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Institutional & Insider Ownership

96.2% of Haemonetics shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Haemonetics and STAAR Surgical's top-line revenue, earnings per share (EPS) and valuation.

Haemonetics has higher revenue and earnings than STAAR Surgical. Haemonetics is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats STAAR Surgical on 10 of the 14 factors compared between the two stocks.